# A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

> **NCT00254436** · PHASE3 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 50 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Procrit (epoetin alfa)

## Key facts

- **NCT ID:** NCT00254436
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10-31
- **Primary completion:** 2004-06-29
- **Final completion:** 2004-06-29
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254436, "A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00254436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*